Browse by author
Lookup NU author(s): Dr Huai Seng Loh
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2014. Società Editrice Universo (SEU). Background and Aims. Escitalopram has widely been recognized as one of the most frequently used antidepressants, with superior tolerability and great efficacy in preventing major depressive disorder (MDD) relapse and recurrence. However, anhedonia, which is a core symptom of MDD, remains difficult to treat. This study investigates the hedonic levels of MDD patients treated with Escitalopram. Materials and Methods. A total of 108 participants, 26 of whom with MDD on Escitalopram, were recruited in this cross sectional study. They were evaluated using the Snaith-Hamilton Pleasure Scale (SHAPS) and Beck Depression Inventory (BDI) questionnaires to assess their hedonic state, general mental health condition and level of depression. Results. Our study shows that most items in the SHAPS scores are significantly different between MDD patients on Escitalopram and the controls. Conclusions. The hedonic capacity remains different between the two groups despite patients with MDD are put on Escitalopram treatment. Escitalopram fails to alleviate the hedonic state of MDD patients. Antidepressants that improve both depressive symptoms and hedonic states should be considered when treating MDD patients in clinical settings.
Author(s): Ng CG, Wong SK, Loh HS, Yee A
Publication type: Article
Publication status: Published
Journal: Clinica Terapeutica
Year: 2014
Volume: 165
Issue: 6
Pages: e384-e390
Acceptance date: 01/01/1900
ISSN (print): 0009-9074
ISSN (electronic): 1972-6007
Publisher: Societa Editrice Universo
URL: https://doi.org/10.7417/CT.2014.1778
DOI: 10.7417/CT.2014.1778
Altmetrics provided by Altmetric
